Akashi Investigating Duchenne Patient Death

Akashi Therapeutics Inc. said it was investigating whether there was a link between its experimental Duchenne muscular dystrophy (DMD) therapy HT-100 and the death of a patient who had been participating in the firm's HALO trial when he experienced serious life-threatening health issues.

Akashi Therapeutics Inc. said it was investigating whether there was a link between its experimental Duchenne muscular dystrophy (DMD) therapy HT-100 and the death of a patient who had been participating in the firm's HALO trial when he experienced serious life-threatening health issues.

The privately held company revealed the death on Feb. 5, posting a notice on the firm's website.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Musculoskeletal

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.